{"eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":11,"description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":11,"seriousNumAffected":1,"seriousNumAtRisk":11,"title":"Glioblastoma Multiforme (GBM)"},{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"title":"Gynecological Cancers"},{"deathsNumAffected":0,"deathsNumAtRisk":8,"description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","id":"EG002","otherNumAffected":0,"otherNumAtRisk":8,"seriousNumAffected":2,"seriousNumAtRisk":8,"title":"Renal Cell Cancer (RCC)"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE v (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Death NOS"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE V (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":8,"numEvents":2}],"term":"Vomiting"}],"timeFrame":"6 weeks"}